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Abstract Background: Alkaptonuria (AKU) is a rare
inherited disorder of the tyrosine metabolic pathway. Our group
is evaluating the use of the homogentisic acid-lowering
agent nitisinone in patients with AKU. A major biochemi-
cal consequence of this treatment is hypertyrosinaemia.
Herein we report the concentration of 20 serum amino
acids over a 36-month period pre- and post-treatment with
nitisinone.
Methods: Fasting serum samples were collected at baseline
(pre-nitisinone), 3 (2 mg nitisinone every other day), 6, 12,
24 and 36 (2 mg nitisinone daily) months. Amino acids
were measured using the Biochrom 30 high-performance
liquid chromatography cation exchange system with ninhy-
drin detection.
Results: Fifty patients [21 female, mean age (standard
deviation) 54.1 (15.6) years (range 25–75); 29 male,
mean age 49.3 (11.6) years (range 22–70 years)] were
included. Following treatment mean tyrosine concentrations
increased seven- to eight-fold (baseline, 69.8 mmol/L; 3
months, 670.7 mmol/L; 6 months, 666.4 mmol/L; 12
months, 692.9 mmol/L; 24 months, 649.4 mmol/L; 36
months, 724.8 mmol/L, p ¼ <0.001 for all visits compared
to baseline).
At baseline mean phenylalanine, aspartic acid and
arginine were outside the normal reference range. Follow-
ing treatment the ratios of phenylalanine/tyrosine, phenyl-
alanine/large neutral amino acids, arginine/branched chain
amino acids and branched chain/aromatic amino acids
decreased (p ¼ <0.05), and the tyrosine/large neutral
amino acid ratio increased (p ¼ <0.0001).
Conclusions: Marked hypertyrosinaemia was observed
following treatment with nitisinone. Noteworthy changes
were also observed in the ratio of several amino acids
following treatment with nitisinone suggesting that the
availability of amino acids for neurotransmitter biosynthesis
and liver function may be altered following treatment with
nitisinone.
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Introduction
Alkaptonuria (AKU, OMIM: 203500) is a rare autosomal
recessive disorder of the tyrosine metabolic pathway,
resulting from a congenital deficiency in the enzyme
homogentisate-1,2-dioxygenase (HGD, E.C.1.12.11.5).
AKU occurs in 1 in 250,000 of the general population
(Phomphutkul et al. 2002), but in certain countries it is
observed more commonly; for instance, in Slovakia it is
estimated to occur in 1 in 19,000 of the population
(Zatkova 2011; Milch 1960).
One of the major metabolic implications of AKU is that
the circulating concentration of homogentisic acid (HGA)
significantly increases. This pathognomonic finding is
thought to be causally responsible for a number of
abnormalities observed in the disease. These include
spondyloarthropathy, characterised by progressive kypho-
scoliosis and impaired spinal and thoracic mobility, as well
as renal and prostate stones, aortic valve stenosis, osteopo-
rosis, fractures and ruptures of tendons, ligaments and
muscle (Ranganath et al. 2013).
Supportive medical management of AKU is the mainstay
of treatment and includes a low-protein diet, analgesia and
arthroplasty (Ranganath et al. 2013). A newer unlicensed
treatment for AKU is the drug nitisinone, a competitive
reversible inhibitor of the enzyme hydroxyphenylpyruvic
acid dioxygenase (HPPD, E.C. 1.13.11.27). It reduces the
formation of HGA and thus has the potential to prevent or
slow the complications observed in patients with AKU.
Previous studies (Phomphutkul et al. 2002; Suwannarat
et al. 2005; Introne et al. 2011; Ranganath et al. 2016;
Milan et al. 2017) have demonstrated the clear biochemical
impact of nitisinone treatment, all demonstrating a > 94%
reduction in urinary HGA. However none have shown
improvement in clinical parameters. This may be for several
reasons, including the following: (1) AKU is a slow
progressive disorder, and thus study duration may not have
been long enough to demonstrate improvement; (2) the
optimal dose of nitisinone may not have been used; and (3)
clinical outcomes measured may not have been appropriate.
At the National Alkaptonuria Centre (NAC) in
Liverpool, nitisinone is being used off licence (patients
are given 2 mg of nitisinone daily, off licence) for treatment
of AKU for all patients in the UK, as it is recognised that
nitisinone is a potential treatment for this debilitating
disease. At the NAC it has also been demonstrated in a
real-life setting that this treatment can reduce urinary HGA
by 94% (Milan et al. 2017).
In contrast nitisinone is already licensed for the
treatment of hereditary tyrosinaemia type 1 (HT1) (HT I,
OMIM 276700) and has proved to be a very efficacious
mode of treatment (McKiernan 2013; McKiernan et al.
2015).
One of the major metabolic consequences of treating
patients with nitisinone in AKU and HT1 is that circulating
tyrosine concentrations markedly increase (Lindstedt et al.
1992; Phomphutkul et al. 2002; Suwannarat et al. 2005;
Introne et al. 2011; Ranganath et al. 2016; Olsson et al.
2015; McKiernan et al. 2015; van Ginkel et al. 2016, 2017;
Milan et al. 2017; Davison et al. 2017).
Hypertyrosinaemia has been observed in patients with
AKU that attended the NAC in Liverpool and during the
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA-1)
clinical trial (Ranganath et al. 2016), which evaluated the
efficacy of different daily doses of nitisinone over a 4-week
period. Beyond this there is nothing reported on the wider
impact of nitisinone on amino acid metabolism.
For many years there has been keen interest in amino
acid metabolism in health and disease, beyond the
traditional setting of inborn errors of metabolism. This is
because amino acids are not only basic metabolites but are
also key regulators in many metabolic pathways. Examples
of areas studied include cognitive function and Alzheimer’s
disease (Ravaglia et al. 2004), gastroesophageal cancer
(Crotti et al. 2017), diabetes (Bi and Henry 2017) and aortic
dissection (Wang et al. 2017).
In addition, while there have been several studies
evaluating serum and plasma amino acid concentrations
both in men and women of a variety of ages (Armstrong
and Stave 1973a, 1973b, 1973c; Rudman et al. 1989;
Caballero et al. 1991; Pitk€anen et al. 2003; Chan et al.
1999; Sarwar et al. 1991; Kouchiwa et al. 2012; Davison
et al. 2015), none have reported fasting serum amino acid
concentrations in patients with AKU pre- and post-
nitisinone therapy.
For the first time, this longitudinal survey reports the
concentration of essential amino acids (valine, leucine,
isoleucine, threonine, methionine, tryptophan, phenylala-
nine, lysine and histidine) and non-essential amino acids
(aspartic acid, asparagine, glutamic acid, glutamine, ala-
nine, glycine, cystine, arginine, tyrosine, serine and proline)
in patients that have attended the NAC with AKU pre- and
post-nitisinone therapy over a 36-month period.
Patients and Analytical Methods
Patients
Protocol for Patients Who Attended the NAC for Treatment
with Nitisinone
The protocol for treatment at the NAC is that patients with
confirmed AKU are commenced on a 2 mg dose of
nitisinone, on alternative days for the first 3 months, which
is then increased to 2 mg daily thereafter. Assessments are
repeated on an annual basis to monitor response to therapy.
JIMD Reports
Nitisinone is given off licence to investigate its safety and
efficacy. It is hypothesised that if HGA levels are reduced
before the onset of overt ochronosis, this might prevent or
stop the development of the debilitating features observed
in AKU.
Inclusion criteria are that individuals must have the
diagnosis of AKU, are residents of England or Scotland and
are over the age of 16 years. Confirmed diagnosis of AKU
is based upon increased urinary excretion of HGA [urine
HGA excretion in healthy volunteers has been demonstra-
ted to be <2.91 mmol/day (Davison et al. 2015)] and is
mandatory for referral to the NAC. Exclusion criteria are
individuals must not be pregnant and/or lactating. All
patients are provided with written information about the
scope of the centre and the assessments they will receive.
All patients at the NAC have biochemical measurements
with clinical assessments performed at baseline, day 4
(2 days post-nitisinone), 3 months, 6 months and 12
months, with annual monitoring thereafter.
Ethical Approval
Data collection and analyses at the NAC have approval
from the Royal Liverpool and Broadgreen University
Hospital Trust Audit Committee (Audit no. ACO3836).
This is not a clinical trial, and therefore ethical approval
was not required. Data obtained is following standard
clinical assessments during the course of providing a
service upon referral to the NAC. Patients are informed
verbally and through patient information leaflets about the
activities of the NAC. Patients are also explicitly informed
that data may be used for publication, and within the NAC
patient information leaflet, the following paragraph is
included:
We could publish results from the study but if we do,
we will make sure that you cannot be identified in
anyway. All data used for publicity or for other
research purposes will ensure total anonymity. Please
let us know when you are visiting the NAC that you
understand and have no objections to this.
No patient has objected to the use of their data.
Subjects Included in the Study
To date (November 2017), 62 patients with AKU have been
enrolled at the NAC for treatment with nitisinone.
Twelve of the sixty-two patients were excluded from this
survey; seven were Welsh patients, and therefore funding
was not available for treatment with nitisinone; three
patients were on nitisinone prior to enrolment at the NAC;
and two patients were not receiving a standard nitisinone
treatment regimen due to corneal keratopathy (Khedr et al.
2017).
Fifty patients [21 female, mean age (standard devia-
tion) 54.1 (15.6) years (range 25–75); 29 male, mean age
49.3 (11.6) years (range 22–70 years)] were included in this
36-month longitudinal survey reporting the biochemical
data obtained from monitoring 20 serum amino acids. This
is an ongoing service, and at the time of preparing this
manuscript, results were not available for all 50 patients at
each time point, apart from baseline. Serum amino acid
results are included from baseline (pre-nitisinone), 3 (2 mg
nitisinone every other day), 6 (2 mg nitisinone daily), 12
(2 mg nitisinone daily), 24 (2 mg nitisinone daily) and 36
(2 mg nitisinone daily) months. Results are not included
after baseline in all patients as individuals have attended the
NAC for different durations and not all patients have
attended planned visits to the NAC.
Analytical Methods
Sample Collection
Serum samples were collected from patients (S-Monovette,
Sarstedt, Germany), centrifuged (10 min at 3,000 rpm) and
stored at 20C until analysis. All serum samples were
collected following an overnight fast (at least 8 h). Patients’
dietary intake of protein was not restricted during this
study.
Measurement of Serum Amino Acids
Serum amino acid concentrations were determined using
Biochrom 30 high-performance liquid chromatography
cation exchange system with ninhydrin detection
(Biochrom, Cambridge, UK). For details of this widely
adopted method for measurement of serum amino acids, see
instructions for use of Biochrom 30+ Amino Acid Analyser
(2018) (version 41 56 1783 IVD instruction for use English
is 16.doc http://www.biochrom.co.uk/user_downloads/?
c¼17).
Calibration and Internal Standards
Calibration was performed using a series of aqueous
standards purchased from Sigma (Dorset, UK) [amino acid
basic standard (product code, A6282); amino acid acidic/
neutral standard (product code, A6407); glutamine (product
code, G8540). Stock calibration standards were made to
2.0 mmol/L, except glutamine which was made to
2.5 mmol/L. All working calibrator concentrations were
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then diluted with loading buffer (Biochrom, product code:
80-2038-70) to a final concentration of 100 mmol/L, except
for cystine which was 50 mmol/L. The diluted working
calibrator also contained the internal standards S-2-amino-
ethyl-L-cysteine hydrochloride (product code, A2636) and
norleucine (product code, N6877) at a final concentration of
200 mmol/L and 5-sulphosalicylic acid at a final concentra-
tion of 91.7 mmol/L.
Internal Quality Control
ClinCheck® plasma control (level 1) for amino acids was
used as internal quality control material (Recipe, Germany).
This contained all amino acids measured, apart from
cystine, which was purchased from Sigma (Dorset, UK)
to make in-house internal quality control material. Inter-
assay coefficient of variation for all 20 amino acids was less
than 4%, as detailed below. [Supplementary data for
individual amino acids – data are summarised as mean
amino acid concentration (mmol/L) (standard deviation),
coefficient of variation (%). Aspartic acid, 12 (0.5), 3.9;
threonine, 109.3 (1.9), 1.8; serine, 96.7 (1.5), 1.5; aspara-
gine, 45 (1.1), 2.3; glutamic acid, 98 (1.2), 1.3; glutamine,
408.9 (9.1), 2.2; glycine, 185.3 (3.0), 1.6; alanine, 405.9
(8.6), 2.1; valine, 233.2 (5.1), 2.2; cystine, 13.2(0.3), 2.4;
methionine, 27.9 (0.9), 3.1; isoleucine, 76.8 (2.3), 3.0;
leucine, 139.4 (3.1), 2.2; tyrosine, 68.3 (1.7), 2.5; phenyl-
alanine, 78.1 (1.8), 2.3; lysine, 171.8 (3.0), 1.7; histidine,
73.5 (1.7), 2.3; tryptophan, 53.5 (1.0), 1.8; arginine, 30.4
(0.8), 2.8; proline, 236.2 (3.7), 3.7].
Sample Preparation
100 mL of calibrator/serum/internal quality control material
was mixed with 100 mL of a solution containing sulfosa-
licylic acid (183.4 mmol/L) to precipitate proteins and
internal standards (S-2-aminoethyl-L-cysteine hydrochlo-
ride and norleucine both at 100 mmol/L). Samples were
then put in the fridge at 4C for 1 h and then centrifuged at
13,000 rpm for 10 min. 60 mL of supernatant was injected
onto the analytical column for analysis.
Data Analysis and Calculations
Amino acid concentrations were calculated offline using
EZCHrom Elite software (version 3.2.1, Agilent, USA).
All statistical analyses were performed using GraphPad
Instat (version 3.10, 2009, CA, USA) and Analyse-it for
Microsoft Excel (version 2.20 Analyse-it Software, Ltd.,
Leeds, UK).
Kolmogorov-Smirnov testing was performed to assess if
serum amino concentrations were normally distributed. For
non-parametric data a Kruskal-Wallis test with a Dunn’s
multiple comparisons post hoc test was used to assess
significant differences in serum amino acid concentrations
pre- and post-treatment with nitisinone. For parametric data
a one-way ANOVA with Tukey post hoc test was applied.
A p value <0.05 was deemed significant.
Amino Acid Ratios
All amino acid concentrations used in calculations were in
mmol/L. Ratios were calculated to assess dietary adequacy
of protein intake (calculation a) (Antener et al. 1981); to
predict phenylalanine, tyrosine and arginine availability to
the brain for neurotransmitter synthesis (calculations b–d)
(Lieberman 1999); and to assess liver metabolism, hepatic
functional reserve and the severity of liver damage
(calculation e) (Fischer et al. 1976).
(a) Phenylalanine to tyrosine ¼ [phenylalanine]/[tyrosine]
(b) Tyrosine to large neutral amino acids ([tyrosine]:
[LNAA]) ¼ [tyrosine]/([tyrosine] + [phenylala-
nine] + [tryptophan] + [leucine] + [isoleu-
cine] + [valine])
(c) Phenylalanine to large neutral amino acids ([phenylal-
anine]/[LNAA]) ¼ [phenylalanine]/([tyrosine] + [phe-
nylalanine] + [tryptophan] + [leucine] + [isoleu-
cine] + [valine])
(d) Arginine to branched chain amino acids ([arginine]/
[BCAA]) ¼ [arginine]/([leucine] + [isoleu-
cine] + [valine])
(e) Branched chain amino acids to aromatic amino acids
([BCAA]/[AAA]) ¼ ([leucine] + [valine] + [isoleu-
cine])/[phenylalanine] + [tyrosine])
Results
Serum Amino Acid Concentrations Pre-nitisinone
Treatment
Table 1 (and Fig. S1, supplementary data) summarises
mean (standard deviation) fasting serum amino acid
concentrations from all patients included in this longitudi-
nal survey. Fifty patients had amino acids measured at
baseline (Table 1, Fig. S1, supplementary data). After
baseline amino acids were not measured in all patients as
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individuals have attended the NAC for different durations
and not all patients attended planned visits to the NAC.
Mean amino acid concentrations were within the normal
reference range at baseline (pre-nitisinone treatment) apart
from phenylalanine, aspartic acid, arginine and cystine
(Table 1), the latter being the only amino acid below the
lower reference range, despite there being a large spread of
concentrations (Fig. S1, supplementary data). All other
amino acids detailed were outside the upper reference
range. Following treatment with nitisinone, these amino
acids did not change significantly over the 36-month period
studied.
Impact of Nitisinone Treatment on Serum Amino Acid
Concentrations
Mean serum tyrosine and tryptophan concentrations were
within the normal reference range pre-nitisinone treatment,
Table 1 Serum amino acid concentrations (mean  standard deviation, mmol/L) in patients attending the National Alkaptonuria Centre over a
36-month period
Amino acid (reference range,
mmol/L)
Baseline
(n ¼ 50)
3 months
(n ¼ 37)
6 months
(n ¼ 29)
12 months
(n ¼ 37)
24 months
(n ¼ 34)
36 months
(n ¼ 20)
Phenylalanine (30–76)E,a 87.42 (13.9) 84.4 (18.3) 91.5 (22.5) 94.5 (13.5) 92.9 (13.6) 97.6 (15.0)
Tyrosine (29–92)a 69.8 (15.7) 670.7 (155.0) 666.4 (162.3) 692.9 (119.8) 649.4 (183.6) 724.8 (116.8)
Tryptophan (40–79)E,a 51.8 (11.5) 50.9 (9.9) 48.5 (11.9) 48.1 (11.1) 51.1 (10.2) 53.5 (14.7)
Glutamine (326–800)b 571.2 (108.0) 476.2 (79.4) 495.1 (81.1) 527.6 (86.0) 525.4 (77.8) 469.4 (103.5)
Asparagine (30–70)b 72.1 (15.1) 64.7 (14.6) 65.3 (17.9) 69.2 (11.0) 61.3 (11.8) 61.4 (9.1)
Aspartic acid (2–5)c 39.8 (9.7) 38.2 (10.9) 37.9 (9.9) 38.1 (6.7) 39.5 (8.7) 45.4 (17.0)
Glutamic acid (26–151)c 128.9 (40.4) 129.2 (56.6) 141.1 (63.5) 151.8 (37.4) 137.5 (32.4) 149.5 (49.2)
Cystine (36–61)d 11.1 (9.3) 6.9 (4.6) 8.3 (8.4) 9.6 (9.1) 13.9 (9.1) 15.7 (13.5)
Methionine (10–41)E,d 25.5 (6.6) 21.8 (4.5) 23.7 (5.9) 25.8 (5.4) 24.4 (4.3) 25.2 (5.3)
Glycine (120–436)e 316.7 (77.6) 299.5 (60.6) 330.5 (61.6) 343.2 (63.2) 329.9 (75.1) 332.6 (74.4)
Isoleucine (20–91)E,e 69.7 (17.6) 63.2 (15.5) 64.5 (15.7) 64.8 (12.1) 66.6 (13.5) 72.5 (18.0)
Leucine (44–169)E,e 148.8 (27.8) 132.1 (28.4) 137.1 (30.7) 139.4 (21.6) 139.7 (20.7) 134.6 (33.1)
Proline (66–330)e 204.3 (89.6) 183.3 (76.3) 207.9 (108.9) 180.4 (63.5) 182.3 (53.3) 182.5 (75.8)
Valine (79–313)E,e 240.4 (43.4) 222.9 (44.6) 226.7 (45.4) 234.2 (36.0) 241.9 (40.2) 250.3 (52.7)
Alanine (112–529)e 462.0 (96.9) 444.8 (92.0) 485.1 (124.8) 427.8 (83.3) 448.5 (82.6) 450.6 (79.5)
Histidine (43–111)E,f 84.1 (12.3) 85.0 (12.8) 86.7 (16.5) 80.7 (9.5) 85.2 (11.7) 79.3 (10.0)
Lysine (66–242)E,f 191.3 (32.2) 180.5 (33.8) 180.45 (38.8) 177.8 (27.9) 183.8 (28.0) 185.6 (27.4)
Arginine (14–102)f 105.2 (23.4) 113.9 (31.1) 116.2 (26.9) 98.1 (13.8) 96.6 (15.9) 108.2 (18.0)
Serine (69–206)g 162.3 (28.7) 149.8 (21.9) 155.5 (29.6) 161.3 (18.6) 157.9 (30.5) 162.4 (25.6)
Threonine (43–218)E,g 132.2 (27.5) 114.5 (25.5) 112.7 (27.0) 112.5 (21.3) 113.4 (23.6) 124.5 (27.8)
Phenylalanine/tyrosine
(0.80–1.0)
1.28 (0.21) 0.13 (0.04) 0.13 (0.03) 0.14 (0.03) 0.16 (0.1) 0.13 (0.04)
Tyrosine/LNAA (0.0–0.14) 0.10 (0.01) 0.55 (0.07) 0.54 (0.10) 0.54 (0.05) 0.52 (0.09) 0.54 (0.06)
Phenylalanine/LNAA
(0.09–0.13)
0.13 (0.01) 0.07 (0.01) 0.07 (0.02) 0.07 (0.01) 0.08 (0.02) 0.07 (0.01)
Arginine/BCAA (0.16–0.23) 0.23 (0.05) 0.27 (0.07) 0.27 (0.07) 0.23 (0.04) 0.22 (0.05) 0.24 (0.04)
BCAA/AAA (Fisher’s ratio)
(2.7–3.5)
2.93 (0.37) 0.56 (0.14) 0.71 (0.86) 0.56 (0.09) 0.71 (0.49) 0.56 (0.13)
All samples were collected in a fasted state (overnight fast >8 h). Baseline refers to pre-nitisinone therapy; at 3 months, patients received 2 mg
nitisinone every other day; after 3 months, patients received 2 mg nitisinone daily. EssentialE amino acids. Amino acid reference ranges were
determined in-house. Amino acid ratio reference ranges were adopted from (Antener et al. 1981; Lieberman 1999; Kouchiwa et al. 2012). LNAA
large neutral amino acids, BCAA branched chain amino acids, AAA aromatic amino acid
a Aromatic
b Amidic
c Acidic
d Sulphur containing
e Aliphatic
f Basic
g Hydroxylic
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and phenylalanine was marginally outside the normal
reference range (Table 1, Fig. S1, supplementary data).
Following treatment with 2 mg nitisinone, every other
day (3-month visit) and daily (all visits after 3 months),
tyrosine concentrations increased to seven- to eight-fold
(p ¼ <0.001, at all visits) (Fig. S1, supplementary data).
Phenylalanine and tryptophan concentrations were not
significantly different over the 36-month period studied
when compared to baseline. Phenylalanine concentrations
did however show an increasing concentration.
Several amino acid ratios were calculated (calculations
a–e) (Table 1). All amino acid ratios were within the
normal range pre-nitisinone treatment, except the phenylal-
anine to tyrosine ratio, which was increased. Following
treatment with nitisinone, all amino acid ratios showed a
significant decrease (see Table 2 for p values; all were
<0.05), apart from the tyrosine to LNAA ratio which
showed a significant increase (p ¼ <0.0001).
Amino Acid Concentrations Showing Differences After
Nitisinone Treatment Started
Table 2 summarises significant differences in amino acid
concentrations that were observed between visits after
nitisinone treatment was started. Apart from tyrosine, the
amino acids asparagine and glutamine showed significant
decreases in concentration post-nitisinone treatment at 24
and 36 months (p ¼ 0.004) and 3, 6 and 36 months,
respectively (p ¼ <0.0001).
Discussion
Herein for the first time, we report the concentration of 20
serum amino acids over a 36-month period in a large cohort
of patients with AKU before and after treatment with
nitisinone. This highly unique longitudinal survey examines
the impact of AKU and its treatment on amino acid
metabolism in a real-life healthcare setting. Traditionally
the focus has been on the tyrosine metabolic pathway when
studying AKU, and several reports have shown that patients
treated with nitisinone have marked hypertyrosinaemia
(Phomphutkul et al. 2002; Suwannarat et al. 2005; Introne
et al. 2011; Ranganath et al. 2016; Olsson et al. 2015;
Milan et al. 2017; Davison et al. 2017). In line with
previous authors we too observed a significant increase in
serum tyrosine following treatment with nitisinone. This
occurs because nitisinone is a reversible competitive
inhibitor of HPPD and essentially creates a new metabolic
defect upstream of its site of action. The biochemical
pattern observed is that which is seen in type 3 tyrosinae-
mia (OMIM: 276710), so-called pseudo-type 3 tyrosinae-
mia.
Recently Milan et al. (2017) reported tyrosine concen-
trations in patients treated with nitisinone over a 24-month
period. In contrast, this longitudinal survey reports the
concentration of 20 serum amino acids, not just tyrosine
over a 36-month period, to establish the wider impact of
treatment with nitisinone on amino acid metabolism.
Moreover data presented herein is in larger cohort of
patients.
Concerns exist over the impact of hypertyrosinaemia, as
tyrosine is transported across the blood-brain barrier and
may result in high brain tyrosine concentrations (Thimm
et al. 2011) and thus increased dopamine concentrations in
cerebral spinal fluid (CSF) as tyrosine is its precursor. A
previous study has demonstrated an increase in homovanil-
lic acid (dopamine metabolite) concentrations in CSF
(Thimm et al. 2011), which suggests that dopamine
metabolism may be altered. Moreover animal studies have
also shown a direct neurotoxic effect of tyrosine, including
oxidative stress (Macedo et al. 2013) and altering DNA
repair (De Pra et al. 2014).
Changes in other aromatic amino acids were fairly
unremarkable. Serum tryptophan remained within the
normal reference range over the 36-month period. Previous
studies in patients with HT-1 treated with nitisinone and in
animal models have suggested that hypertyrosinaemia
observed following treatment may reduce the biosynthesis
of serotonin and thus be responsible for altered cognitive
function and behavioural problems observed in HT-1
Table 2 Serum amino acid concentrations that were significantly
different in patients attending the National Alkaptonuria Centre over a
36-month period
Amino acid p
Change in amino acid
concentration observed
compared to baseline
Change
observed
Asparagine 0.004 24 and 36 months Decrease
Glutamine <0.0001 3, 6 and 36 months Decrease
Tyrosine <0.0001 3, 6, 12, 24 and 36 months Increase
Phenylalanine/
tyrosine
<0.0001 3, 6, 12, 24 and 36 months Decrease
Tyrosine/
LNAA
<0.0001 3, 6, 12, 24 and 36 months Increase
Phenylalanine/
LNAA
<0.0001 3, 6, 12, 24 and 36 months Decrease
Arginine/
BCAA
<0.01 3 months Decrease
<0.05 6 months
BCAA/AAA
(Fisher’s
ratio)
<0.0001 3, 6, 12, 24 and 36 months Decrease
Baseline refers to pre-nitisinone therapy; at 3 months, patients
received 2 mg nitisinone every other day; after 3 months, patients
received 2 mg nitisinone daily. LNAA large neutral amino acids, BCAA
branched chain amino acids, AAA aromatic amino acid
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(De Laet et al. 2011; Thimm et al. 2012; Masurel-Paulet
et al. 2008; Bendadi et al. 2014; van Ginkel et al. 2016).
Evidence of this is sparse, and only one small study has
reported decreased CSF concentrations of 5-hydroxyindole
acetic acid (serotonin metabolite) (Thimm et al. 2011).
Mechanisms that have been proposed suggest (1) that
tyrosine may inhibit tryptophan hydroxylase activity, which
is the rate-limiting step in serotonin metabolism, and (2)
tyrosine may compete for transport into the central nervous
system via a common large neutral amino acid transporter
(LAT-1) and thus reduce tryptophan uptake required for
serotonin biosynthesis (Hillgartner et al. 2016). It is
reassuring that tryptophan did not change following
nitisinone in the present data set.
Phenylalanine showed an increasing trend over the
period studied. This is in contrast to reports in patients
with HT-1 that have shown reduced concentrations of
phenylalanine following nitisinone therapy (Daly et al.
2012; van Vliet et al. 2014). While HT1 patients are on a
protein-restricted diet, it is still thought that nitisinone itself
may be the cause of the lower phenylalanine observed. The
underlying mechanism for this is not fully understood
(Harding et al. 2014). It has been postulated that hyper-
tyrosinaemia may also reduce phenylalanine uptake into the
brain due to competition for the LAT-1 (van Ginkel et al.
2016). This supposition may be supported as a significant
increase in the ratio calculated in equation b (tyrosine to
large neutral amino acids) and significant decrease in the
ratios calculated in equations c–d (phenylalanine to large
neutral amino acids; arginine to branched chain amino
acids) were observed after nitisinone treatment implying
that amino acid availability to the brain may be reduced,
with the exception of tyrosine. The ratios are proposed to
be a more reliable measure of the availability of tyrosine,
phenylalanine and arginine to the brain instead of individ-
ual amino acid concentrations (Lieberman 1999).
While the significant decrease in the ratios implies a
reduced availability of the detailed amino acids to the brain
for neurotransmitter synthesis, it does not fit with the serum
concentrations of phenylalanine observed in the current
survey. However the concentration of phenylalanine in
serum does not necessarily reflect that which is seen in
CSF.
Of note pre-nitisinone therapy, the phenylalanine to
tyrosine ratio was increased compared to the normal
reference range (Antener et al. 1981). The reason for this
is uncertain, as typically this ratio is monitored to assess the
flux of phenylalanine to tyrosine and the adequacy of
protein intake. One may postulate that phenylalanine
hydroxylase activity may be reduced, thus causing a mild
increase in the ratio. Reduced enzyme activity has been
reported in individuals with increased inflammation
(Wannemacher et al. 1976). As AKU is a chronic disease
process, it is possible that inflammatory processes are
altered; however this was not assessed. Another possibility
is that the increase in phenylalanine is an artefact; however
this is unlikely as samples were centrifuged immediately
and stored at 20C until they were analysed.
Following the commencement of nitisinone treatment,
the BCAA to AAA ratio significantly decreased, potentially
misleadingly suggesting that following treatment liver
function was altered. The reason for the change in ratio is
the inability to degrade tyrosine, an aromatic acid, greatly
increasing the denominator of the ratio. However as
tyrosine is in such vast quantities from a metabolic defect
in the tyrosine metabolic pathway, and not related to liver
function, one cannot use this ratio reliably to make an
assessment of liver function. Prior to starting treatment, the
BCAA to AAA ratio was within the normal range
indicating that patients had normal liver function.
A number of changes were observed in several amino
acids over the course of this longitudinal survey (Fig. S1),
but none appear to be related to treatment with nitisinone
and are not consistent at all-time points evaluated. It is
thought that these findings are likely to reflect the natural
fluctuation one would observe in amino acids, and no
reliable conclusions can be drawn from these data.
Of particular interest were the mean amino acid concen-
trations (Table 1) that were outside the normal reference
range independent of nitisinone therapy. Specifically
cystine was lower than the lower reference range, and
arginine and aspartic acid concentrations were higher.
Decreases in cystine can be observed due to haemolysis,
delayed separation and or platelet/leukocyte contamination
(Perry and Hansen 1969; Bowron et al. 2012). As discussed
previously samples were separated immediately from cells
and stored before analysis at 20C, thus eliminating this
as a mechanism for the low cystine concentrations
observed. One may postulate that the low cystine observed
is a result of its reaction with glutathione, via glutathione-
cystine transhydrogenase activity to form cysteine as part of
the body’s defence against oxidative stress. The rationale
for this is that AKU is accompanied by increased oxidative
stress (Davison et al. 2016), which, in part, results from the
benzoquinone polymers that are produced from the high
concentrations of HGA observed in AKU. Cysteine was not
measured in this longitudinal survey but should be
evaluated to assess the validity of this hypothesis.
It has been proposed that increases in aspartic acid and
glutamic acid can be observed from the deamination of
asparagine and glutamine, respectively, due to delayed
separation and haemolysis (Perry and Hansen 1969,
Bowron et al. 2012). Samples did not visually appear to
be haemolysed; however no haemolytic indices were
measured so this cannot be completely excluded as a
contributory factor. Moreover samples were separated
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immediately from cells and stored before analysis at
20C. One possibility is that the proposed increased
oxidative stress observed in AKU results in the increased
formation of glutamic acid from glutamine. Glutamic acid
is the precursor for glutathione which is essential for
maintaining the redox state of the cell (Davison et al. 2016).
If deamination of asparagine to aspartic acid was the
cause of increased aspartic acid in this survey, one would
have expected lower concentrations of asparagine to be
observed, which was not the case. The significance of this
finding is unknown.
Conclusions
Significant hypertyrosinaemia has been demonstrated
following treatment with the HGA-lowering drug nitisi-
none. The implications of the hypertyrosinaemia are in
large unknown. However in this longitudinal survey, it has
been demonstrated that amino acid ratios have been
significantly altered suggesting that the availability of
amino acids for neurotransmitter biosynthesis and liver
function may be altered.
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